Literature DB >> 11481629

Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time.

H J Lin1, L B Seeff, L Barbosa, F B Hollinger.   

Abstract

A total of 240 stored serum specimens from 30 transfusion recipients and 120 blood donors from the Transfusion-Transmitted Viruses Study (TTVS) were evaluated with the objective of establishing transmission of hepatitis C virus (HCV) by specific blood donors. Phylogenetic analysis of hypervariable region 1 (HVR1) and HCV genotyping were performed on the genomic region encoding amino acids 329 to 410. Amino acid distances between HVR1 sequences were calculated by the Kimura formula. Bootstrap analysis of HVR1 sequences provided support for linking recipients to specific donors. Linear regression analysis showed no differences between donor and recipient HVR1 sequences 7.9 weeks posttransfusion, but donor and recipient sequences diverged thereafter (r = 0.690). The initial lag phase in the evolution of HVR1 in the infected recipient was attributed to the time required to mount host immunologic defenses against the virus. Within-recipient divergence in HVR1 was determined from analyses of serial specimens collected within 2 weeks after the alanine transaminase peak, at the end of the original study (1974-1979), and in the follow-up study (1987-present). HVR1 remained invariant over a period of 6.7 to 9.5 days (95% CI) during acute infection. Within-patient divergence in HVR1 increased over a period of 11 to 15 years (r = 0.771), reaching the degree of divergence observed between unlinked subjects. In cases in which transfusion involved more than one HCV subtype, only one of the HCV subtypes established infection in the recipient. Subtype-specific differences in HVR1 were shown.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481629     DOI: 10.1053/jhep.2001.26635

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

Review 2.  Hepatitis C virus: Promising discoveries and new treatments.

Authors:  Juliana Cristina Santiago Bastos; Marina Aiello Padilla; Leonardo Cardia Caserta; Noelle Miotto; Aline Gonzalez Vigani; Clarice Weis Arns
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.

Authors:  Gerond Lake-Bakaar; Lynda Ruffini; Petr Kuzmic
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

4.  Cross-reactivity of hypervariable region 1 chimera of hepatitis C virus.

Authors:  Bing-Shui Xiu; Shi-Gan Ling; Xiao-Guo Song; He-Qiu Zhang; Kun Chen; Cui-Xia Zhu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.

Authors:  Richard J P Brown; Natalia Hudson; Garrick Wilson; Shafiq Ur Rehman; Sara Jabbari; Ke Hu; Alexander W Tarr; Persephone Borrow; Michael Joyce; Jamie Lewis; Lin Fu Zhu; Mansun Law; Norman Kneteman; D Lorne Tyrrell; Jane A McKeating; Jonathan K Ball
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

6.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Authors:  Isabelle Moreau; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-07-09       Impact factor: 4.099

7.  Separation of Hepatitis C genotype 4a into IgG-depleted and IgG-enriched fractions reveals a unique quasispecies profile.

Authors:  Isabelle Moreau; Hilary O'Sullivan; Caroline Murray; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-09-23       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.